Mechelen, Belgium and Osaka, Japan; 16 April 2007 - Galapagos NV (Euronext & LSE: GLPG) announced today that its BioFocus DPI service division has signed two new collaborations with Ono Pharmaceutical Company Ltd. (Tokyo: OSA). These collaborations build on the successful relationship between Ono and DPI, which began in 2004. Under the first collaboration announced today, BioFocus DPI will use selected compounds from its SoftFocus and other synthetic small molecule collections to perform high throughput screening for Ono’s drug discovery program. In the second collaboration, BioFocus DPI will apply its medicinal and computational chemistry and ADME profiling expertise in multiple medicinal chemistry projects for Ono.
